Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology

References

• Hoff A, Toth BB, Altundag K, et al. The frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826–836.
   PubMed Web of Science ®Google Scholar
• Adamo V, Caristi N, Saccà MM, et al. Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients. Expert Opin Pharmacother. 2008;9(8):1351–1361.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med. 2005.
   Google Scholar
• Miksad RA, Lai KC, Dodson TB, et al. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist. 2011;16(1):121–132.
   PubMed Web of Science ®Google Scholar
• Stewart ST, Lenert L, Bhatnagar V, et al. Utilities for prostate cancer health states in men aged 60 and older. Med Care. 2005;43(4):347–355.
   PubMed Web of Science ®Google Scholar
• Loeb S, Roehl KA, Helfand BT, et al. Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. Urology. 2008;72(4):887–891.
   Google Scholar
• Setabutr D, Hales NW, Krempl GA. Necrotizing fasciitis secondary to bisphosphonate-induced osteonecrosis of the jaw. Am J Otolaryngol [Internet]. 2010 [cited 2009 Mar 26];31(2):127–129. doi:10.1016/j.amjoto.2008.11.002.
   PubMed Web of Science ®Google Scholar
• Randi L, De Martino I, Fasciolo A, et al. Osteonecrosis of jaw (ONJ): sometimes a life-threatening event. Literature review and two cases. Ann Stomatol (Roma). 2014;5(2 Suppl): 33–34. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377653/
   Google Scholar
• Mondello P, Pitini V, Arrigo C, et al. Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. Springerplus. 2014;3: 123. doi:10.1186/2193-1801-3-123. eCollection 2014
   PubMed Web of Science ®Google Scholar
• Kaehling C, Streckbein P, Schmermund D, et al. Lethal cervical abscess following bisphosphonate related osteonecrosis of the jaw. J Craniomaxillofac Surg. 2014;42(7):1203–1206. doi:10.1016/j.jcms.2014.02.009.
   PubMed Web of Science ®Google Scholar
• Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008;26:4037–4038.
   PubMed Web of Science ®Google Scholar
• Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122(1):181–188.
   PubMed Web of Science ®Google Scholar
• Smidt-Hansen T, Folkmar TB, Fode K, et al. Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg. 2013;71(9):1532–1540.
   PubMed Web of Science ®Google Scholar
• Giancola F, Campisi G, Russo LL, et al. Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report?. Ann Stomatol. 2013;4(Suppl 2):20–21.
   PubMedGoogle Scholar
• Kim DW, Jung YS, Park HS, et al. Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral MaxillofacSurg. 2013;4(Suppl 2):20–21.
   Google Scholar
• Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369–376.
   PubMed Web of Science ®Google Scholar
• Khosla, S., Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral research. J Bone Miner Res. 2007;22(10):1479–1491.
   PubMed Web of Science ®Google Scholar
• Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008;26:4037–4038.
   PubMed Web of Science ®Google Scholar
• Troeltzsch M, Woodlock T, Kriegelstein S, et al. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc. 2012;78:c85.
   PubMedGoogle Scholar
• Junquera L, Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg. 2008;66(7):1516–1517.
   PubMed Web of Science ®Google Scholar
• Mawardi H, Treister N, Richardson P, et al. Sinus tracts—an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg. 2009;67(3):593–601.
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg. 2009;67(suppl 1):2–12.
   PubMed Web of Science ®Google Scholar
• Colella G, Campisi G, Fusco V. American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the jaws—2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg. 2009;67(12):2698–2699.
   PubMed Web of Science ®Google Scholar
• Fedele S., Porter SR, D’Aiuto F, et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med. 2010;123(11):1060–1064.
   PubMed Web of Science ®Google Scholar
• Yarom N, Fedele S, Lazarovici TS, et al. Is exposure of the jawbone mandatory for establishing the diagnosis of bisphosphonate-related osteonecrosis of the jaw? J Oral Maxillofac Surg. 2010;68(3):705.
   PubMed Web of Science ®Google Scholar
• Hutchinson M, O’Ryan F, Chavez V, et al. Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg. 2010;68(9):2232–2240.
   PubMed Web of Science ®Google Scholar
• Patel S, Choyee S, Uyanne J, et al. Non-exposed bisphosphonate related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines. Oral Dis. 2012;18(7):625–632.
   PubMed Web of Science ®Google Scholar
• Bedogni A, Fusco V, Agrillo A, et al. Learning from experience. Proposal of a refined definition and staging system for bisphosphonate- related osteonecrosis of the jaw (BRONJ). Oral Dis. 2012;18(6):621–623.
   PubMed Web of Science ®Google Scholar
• Campisi G, Lo Russo L, Agrillo A, et al. BRONJ expert panel recommendation of the Italian Societies for Maxillofacial Surgery (SICMF) and Oral Pathology and Medicine (SIPMO) on bisphosphonate-related osteonecrosis of the jaws: risk assessment, preventive strategies and dental management. Italian J Maxillofac Surg. 2011;22(2):103–124.
   Google Scholar
• Schiodt M, Reibel J, Oturai P, et al. Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;117(2):204–213.
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg. 2014;72(10):1938–1956. doi:10.1016/j.joms.2014.04.031.
   PubMed Web of Science ®Google Scholar
• Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3–23.
   PubMed Web of Science ®Google Scholar
• Otto S, Marx RE, Tröltzsch M, et al. Comments on “diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus”. j bone Miner Res. 2015;30:1113–1115. doi:10.1002/jbmr.2525.
   PubMed Web of Science ®Google Scholar
• Fusco V, Galassi C, Berruti A, et al. Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol. 2011;29(17):e521–e522; author reply e523-4. doi:10.1200/JCO.2011.35.1551.
   Google Scholar
• Fedele S, Bedogni G, Scoletta M, et al. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg. 2015;53(1):13–17.
   PubMed Web of Science ®Google Scholar
• Bedogni A, Fedele S, Bedogni G, et al. Staging of jaw osteonecrosis requires computed tomography for accurate definition of the extent of bony disease. Br JMaxillofac Surg. 2014;52:603–608.
   Web of Science ®Google Scholar
• Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. J Oral Maxillofac Surg. 2009;67(5 Suppl):13–18. doi:10.1016/j.joms.2008.10.005.
   PubMed Web of Science ®Google Scholar
• Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009;67(suppl 5):61–70.
   PubMed Web of Science ®Google Scholar
• Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol. 2007;4:711–721.
   PubMedGoogle Scholar
• Campisi G, Fedele F, Fusco V, et al. Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents. Future Oncol. 2014;10:257–275.
   PubMed Web of Science ®Google Scholar
• Santini D, Galluzzo S, Vincenzi B, et al. New developments of aminobisphosphonates: the double face of Janus. Ann Oncol. 2007;18(suppl6):vi164–vi167.
   PubMedGoogle Scholar
• Vincenzi B, Napolitano A, Zoccoli A, et al. Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw. J Hematol Oncol. 2012;5:56.
   PubMed Web of Science ®Google Scholar
• Arduino PG, Menegatti E, Scoletta M, et al. Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws. J Oral Pathol Med. 2011;40(6):510–515. doi:10.1111/j.16000714.2010.01004.x.
   PubMed Web of Science ®Google Scholar
• Allegra A, Alonci A, Penna G, et al. Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws. Acta Haematol. 2010;124(2):79–85. doi:10.1159/000313787.
   PubMed Web of Science ®Google Scholar
• Saad F, Brown JE, Poznak CV, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341–1347.
   PubMed Web of Science ®Google Scholar
• Toole J. Osteonecrosis of the jaws. Rheumatology (Oxford). 2015;54(10):1755–1756. doi:10.1093/rheumatology/kev094. Epub 2015 Apr 14.
   PubMed Web of Science ®Google Scholar
• Aghaloo TL, Dry SM, Mallya S, et al. Stage 0 osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg [Internet]. 2014 [cited 2014 Jan 4];72(4):702–716. doi:10.1016/j.joms.2013.09.008.
   PubMed Web of Science ®Google Scholar
• Niibe K, Ouchi T, Iwasaki R, et al. Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab. J Prosthodont Res. 2015;59(1):3–5. doi:10.1016/j.jpor.2014.08.001.
   PubMed Web of Science ®Google Scholar
• Yarom N, Elad S, Madrid C, et al. Osteonecrosis of the jaws induced by drugs other than bisphosphonates-a call to update terminology in light of new data. Oral Oncol. 2010;46:e1.
   PubMed Web of Science ®Google Scholar
• Hamadeh IS, Ngwa BA, Gong Y. Drug induced osteonecrosis of the jaw. Cancer Treat Rev [Internet]. 2015 [cited 2015 Apr 21];41(5):455–464. doi:10.1016/j.ctrv.2015.04.007.
   PubMed Web of Science ®Google Scholar
• McArthur HL, Estilo C, Huryn J, et al. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol. 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement). 2008;9588. Available from: http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/9588
   Google Scholar
• Aragon-Ching JB, Ning YM, Latham L, et al. Osteonecrosis of the jaw (ONJ) in androgen-independent prostate cancer (AIPC) patients receiving ATTP (bevacizumab, docetaxel, thalidomide, and prednisone). J Clin Oncol. 2007;25:19594.
   Google Scholar
• Aragon-Ching JB, Dahut WL. Osteonecrosis of the jaw and the use of antiangiogenic agents: just an association? Oncologist. 2008;13:1314.
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Ning YM, Chen C, et al. Higher incidence of Osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest. 2009;27:221–226.
   PubMed Web of Science ®Google Scholar
• Ayllon J, Launay-Vacher V, Medioni J, et al. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol. 2009;20:600–601.
   PubMed Web of Science ®Google Scholar
• Brunello A, Saia G, Bedogni A, et al. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone. 2009;44:173–175.
   PubMed Web of Science ®Google Scholar
• Bozas G, Roy A, Ramasamy V, et al. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. Onkologie. 2010;33:321–323.
   PubMedGoogle Scholar
• Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:463–469.
   PubMed Web of Science ®Google Scholar
• Koch FP, Walter C, Hansen T, et al. Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg. 2011;15:63–66.
   PubMedGoogle Scholar
• Nicolatou-Galitis O, Migkou M, Psyrri A, et al. Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:234–238.
   PubMed Web of Science ®Google Scholar
• Fleissig Y, Regev E, Lehman H. Sunitinib-related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:e1–e3.
   PubMed Web of Science ®Google Scholar
• Agrillo A, Nastro Siniscalchi E, Facchini A, et al. Osteonecrosis of the jaws in patients assumine bisphosphonates and sunitinib: two case reports. Eur Rev Med Pharmacol Sci. 2012;16:952–957.
   PubMed Web of Science ®Google Scholar
• MHRA. Bevacizumab and sunitinib: risk of osteonecrosis of the jaw. Drug Safety Update. 2011. Available from: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON105745
   Google Scholar
• Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082–3092.
   PubMed Web of Science ®Google Scholar
• Fusco V, Bedogni A, Campisi G. Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab. Support Care Cancer. 2014;22:1737–1738.
   PubMed Web of Science ®Google Scholar
• Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–761.
   PubMed Web of Science ®Google Scholar
• Fusco V, Porta C, Saia G, et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature. Clin Genitourin Cancer. 2015;13(4):287–294. doi:10.1016/j.clgc.2014.12.002.
   PubMed Web of Science ®Google Scholar
• Bozas G, Allgar V, Greenwood G, et al. Osteonecrosis of the jaw in patients treated with sunitinib and zoledronic acid (abstract e15116). J Clin Oncol. 2011. Available from: http://meetinglibrary.asco.org/content/82466-102
   Google Scholar
• Beuselinck B, Wolter P, Karadimou A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer. 2012;107:1665–1671.
   PubMed Web of Science ®Google Scholar
• Gabbert TI, Hoffmeister B, Felsenberg D. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. J Cancer Res Clin Oncol. 2014; 141; 749–58
   PubMed Web of Science ®Google Scholar
• Greuter S, Schmid F, Ruhstaller T, et al. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol. 2008;19:2091–2092.
   PubMed Web of Science ®Google Scholar
• Guarneri V, Miles D, Robert N, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonates therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122:181–188.
   PubMed Web of Science ®Google Scholar
• Bettini G, Blandamura S, Saia G, et al. Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. BMJ Case Rep. 2012;2012. doi:10.1136/bcr-2012-007284.
   PubMedGoogle Scholar
• Brunamonti Binello P, Bandelloni R, Labanca M, et al. Osteonecrosis of the jaws and bevacizumab therapy: a case report. Int J Immunopathol Pharmacol. 2012;25(3):789–791.
   PubMed Web of Science ®Google Scholar
• Tzermpos F, Ismail A, Pavli M, et al. Osteonecrosis of the mandible in a patient with lung adenocarcinoma undergoing anti-angiogenic therapy with bevacizumab. Oral Surg. 2015;9(1):40–46.
   Google Scholar
• Fusco V, Fasciolo A, Pertino A, et al. Bevacizumab - related osteonecrosis of jaw in a rectal cancer patient never treated with bisphosphonates. Ann Stomatol. 2014. Available from: www.ncbi.nlm.nih.gov/pmc/articles/PMC4252873.
   PubMedGoogle Scholar
• Hopp RN, Pucci J, Santos-Silva AR, et al. Osteonecrosis after administration of intravitreous bevacizumab. J Oral Maxillofac Surg [Internet]. 2012 [cited 2011 Jul 14];70(3):632–635. doi:10.1016/j.joms.2011.02.104.
   PubMed Web of Science ®Google Scholar
• Pakosch D, Papadimas D, Munding J, et al. Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac Surg. 2013;17(4):303–306. doi:10.1007/s10006-012-0379-9.
   PubMedGoogle Scholar
• Santos-Silva AR, Belizário Rosa GA, Castro Júnior GD, et al. Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115:e32–e36.
   PubMed Web of Science ®Google Scholar
• Agostino NM, Gingrich R, Drabick JJ. Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature. Adv Urol. 2010;2010:687043.
   PubMedGoogle Scholar
• Magremanne M, Lahon M, De Ceulaer J, et al. Unusual bevacizumabrelated complication of an oral infection. J Oral Maxillofac Surg. 2013;71:53–55.
   PubMed Web of Science ®Google Scholar
• Ngamphaiboon N, Frustino JL, Kossoff EB, et al. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab. Clin Breast Cancer. 2011;11(4):252–257. doi:10.1016/j.clbc.2011.02.001.
   PubMed Web of Science ®Google Scholar
• Lescaille G, Coudert AE, Baaroun V, et al. Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jawin cancer patients. Bone. 2014;58:103–107.
   PubMed Web of Science ®Google Scholar
• FDA report on aflibercept: Center for drug evaluation and research. Application number 125418Orig1s000. Clin Rev. Aflibercept/Zaltrap. 100, 141. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/125418Orig1s000MedR.pdf
   Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28):3499–3506. [Epub 2012 Sep 4].
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Frankel P, Margolin KA, et al. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011;17(20):6574–6581. doi:10.1158/1078-0432.CCR-11-1463.
   PubMed Web of Science ®Google Scholar
• Ponzetti A, Pinta F, Spadi R, et al. Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Tumori. 2015; doi:10.5301/tj.5000405. Epub ahead of print
   PubMedGoogle Scholar
• Hartmann JT, Haap M, Kopp, HG et al. Tyrosine Kinase inhibitors- a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10(5):470–481.
   PubMed Web of Science ®Google Scholar
• Gilabert M, Provansal M, Cappiello M, et al. Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma. Br J Cancer [Internet]. 2013 [cited 2013 Sep 17];109(7):1750–1754. doi:10.1038/bjc.2013.516.
   PubMed Web of Science ®Google Scholar
• Balmor GR, Yarom N, Weitzen R. Drug-induced palate osteonecrosis following nasal surgery. Isr Med Assoc J. 2012;14:193–194.
   PubMed Web of Science ®Google Scholar
• Marino R, Orlandi F, Arecco F, et al. Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust Dent J. 2014 Dec 4. doi:10.1111/adj.12254. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31:3639–3646.
   PubMed Web of Science ®Google Scholar
• Bertoldo F, Silvestris F, Ibrahim T, et al. Targeting bone metastatic cancer: role of the mTOR pathway. Biochim Biophys Acta. 2014;1845(2):248–254. doi:10.1016/j.bbcan.2014.01.009.
   PubMed Web of Science ®Google Scholar
• Prati V, Ortega C, Aglietta M Caso clinico di Osteonecrosi da inibitore di m-TOR. Abstract Convegno Osteonecrosi dei mascellari (ONJ): ruolo della Rete Oncologica del Piemonte e della Valle d’Aosta Update 2011 (32). [2015 Jan 2]. Available from: http://www.reteoncologica.it/images/stories/ONJ/alessandria%20onj%202011-abstract.pdf
   Google Scholar
• Gnant M. The role of mammalian target of rapamycin (mTOR) inhibition in the treatment of advanced breast cancer. Curr Oncol Rep. 2013;15(1):14–23. doi:10.1007/s11912-012-0277-1.
   PubMed Web of Science ®Google Scholar
• Martini V, Bonacina R, Mariani U. Osteonecrosis of the jaw in a patient treated with zoledronic acid and everolimus: a case report. Ann Stomatol. 2014. Available from: www.ncbi.nlm.nih.gov/pmc/articles/PMC4252873
   Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529. doi:10.1056/NEJMoa1109653.
   PubMed Web of Science ®Google Scholar
• Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol. 2014;25(12):2357–2362. doi:10.1093/annonc/mdu456.
   PubMed Web of Science ®Google Scholar
• Gnant M, Baselga J, Rugo HS, et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst. 2013;105(9):654–663. doi:10.1093/jnci/djt026.
   PubMedGoogle Scholar
• FDA report on everolimus. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022334s029lbl.pdf
   Google Scholar
• Aapro M, Andre F, Blackwell K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol. 2014;25(4):763–773. doi:10.1093/annonc/mdu021.
   PubMed Web of Science ®Google Scholar
• Owosho A, Scordo M, Yom SK, et al. Osteonecrosis of the jaw a new complication related to ipilimumab. Oral Oncology. 2015; doi:10.1016/j.oraloncology.2015.08.014. (Impact Factor: 3.61)
   Web of Science ®Google Scholar
• Edwards BJ, Gounder M, McKoy JM, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008;9(12):1166–1172. doi:10.1016/S1470-2045(08)70305-X.
   PubMed Web of Science ®Google Scholar
• Fusco V Baraldi A, Fasciolo A, et al. ONJ: Impact of Italian patients, and role of Italian physicians, dentists, and researchers in the growing evidence of a “new” disease. Working Paper of Public Health (12/2012) (online journal). Available from: http://www.ospedale.al.it/AllegatiPaginaDescrizione/Paper-12_2012_new.pdf.
   Google Scholar
• Kruger TB, Sharikabad MN, Herlofson BB. Bisphosphonate-related osteonecrosis of the jaw in four Nordic countries and an indication of under-reporting. Acta Odontol Scand. 2013;71(6):1386–1390.
   PubMed Web of Science ®Google Scholar
• De Boissieu P, Trenque T. Standardized classification unsuitable for spontaneous reporting: the example of osteonecrosis of the jaw. Expert Opinion Drug Saf. 2015;14(7):1015.21.
   PubMed Web of Science ®Google Scholar